NYSE - Delayed Quote USD

Glaukos Corporation (GKOS)

Compare
133.00 -0.89 (-0.66%)
At close: September 3 at 4:00 PM EDT
133.12 +0.12 (+0.09%)
After hours: September 3 at 7:52 PM EDT
Loading Chart for GKOS
DELL
  • Previous Close 133.89
  • Open 135.63
  • Bid 53.01 x 1100
  • Ask --
  • Day's Range 132.00 - 136.60
  • 52 Week Range 59.22 - 136.60
  • Volume 583,638
  • Avg. Volume 553,846
  • Market Cap (intraday) 7.357B
  • Beta (5Y Monthly) 1.03
  • PE Ratio (TTM) --
  • EPS (TTM) -3.18
  • Earnings Date Oct 30, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 136.91

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

www.glaukos.com

907

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GKOS

View More

Performance Overview: GKOS

Trailing total returns as of 9/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GKOS
67.32%
S&P 500
15.91%

1-Year Return

GKOS
77.59%
S&P 500
22.44%

3-Year Return

GKOS
122.41%
S&P 500
21.86%

5-Year Return

GKOS
106.81%
S&P 500
88.93%

Compare To: GKOS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GKOS

View More

Valuation Measures

Annual
As of 9/3/2024
  • Market Cap

    7.31B

  • Enterprise Value

    7.20B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    19.26

  • Price/Book (mrq)

    10.99

  • Enterprise Value/Revenue

    21.08

  • Enterprise Value/EBITDA

    -57.89

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -46.41%

  • Return on Assets (ttm)

    -7.96%

  • Return on Equity (ttm)

    -27.49%

  • Revenue (ttm)

    341.72M

  • Net Income Avi to Common (ttm)

    -158.61M

  • Diluted EPS (ttm)

    -3.18

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    261.66M

  • Total Debt/Equity (mrq)

    23.89%

  • Levered Free Cash Flow (ttm)

    -26.14M

Research Analysis: GKOS

View More

Company Insights: GKOS

Research Reports: GKOS

View More

People Also Watch